Jeanne has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD) and Venture Investments.  She spent 11 years in Licensing and Acquisition (L&A), including Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, and before that as Director in the Business Development group at GlaxoSmithKline.

Jeanne spent nearly 10 years (2012-2022) as Vice President Venture Investment in J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. During that period, she was based in London, leading investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer.  She represented JJDC on the Board of Directors of over a dozen companies, including Aelix Therapeutics, Asceneuron SA, Aviado Bio, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, S-Biomedic, Syndesi, T-Rex.  Dr Bolger also represented JJDC’s LP investments in multiple Venture Capital Funds in UK and Europe as well as representing J&J’s interests in other funding vehicles including incubators and accelerators.

Sandra Powell-Elliott, the vice president of Innovation and Health Ventures at Hackensack Meridian Health, has been named to the Becker’s Healthcare 2022 list “Women Power Players in Health IT”.

Sandra Powell-Elliott will also be a featured speaker at Becker’s Hospital Review’s 7th Annual Health IT + Revenue Cycle Conference, which will take place in Chicago from Oct. 4-7. She will discuss “How to be a Daredevil Innovator in Healthcare.”

Sandra Powell-Elliott’s role at Hackensack Meridian Health is to foster the internal development of an innovative culture, while also bringing innovative and transformative solutions from outside of the organization to the forefront of the organization’s strategic planning efforts. Through the development of the Bear’s Den investment and innovation program, Sandra’s efforts have enabled HMH to invest in early stage, innovative ideas and technologies to better meet the needs of patients and the clinicians who treat them.

In addition, Sandra closely works with the researchers of the Hackensack Meridian Center of Discovery and Innovation (CDI) to license new discoveries, create spin-out opportunities, and also identify collaborative opportunities with large medical device and pharmaceutical companies.

Niall leads product, implementation, and customer success as well as strategic partnerships. Prior to Oneview, he was in management consulting including roles with Accenture and Deloitte.

Prof. Dr. med. Mathias Goyen is currently the Chief Medical Officer EMEA for GE HealthCare. Mathias is responsible for leading GE Healthcare’s medical, clinical, and evidence generation strategies for product modalities in Europe, the Middle East & Africa. Together with his team he provides leadership in healthcare economics and outcomes research and comparative effectiveness research to develop customer value propositions for new and existing products.

Mathias began his career as a diagnostic Radiologist working at Essen and Hamburg/Germany. He was appointed Professor of Diagnostic Radiology at the University of Hamburg/Germany in 2010. Mathias’ previous experience also includes 5 years as Managing Director of UKE Consult and Management GmbH, a subsidiary of the University Medical Center Hamburg where he was responsible for the overall consulting and foreign business of the University Medical Center Hamburg. Together with the leadership team of the hospital Mathias established a Comprehensive Cancer Center linking clinical medicine with new oncologic research strategies.

Mathias holds a medical degree (MD) from the University of Bochum, Germany. He has been secretary general of the German Chinese Society of Medicine, Berlin, from 2005 – 2019.

Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., became Amgen’s Chief Medical Officer (CMO) in June 2023.

Burton had previous experience working for Amgen, as Global Development Leader from 2002 to 2005, following the company’s merger with Immunex. Prior to his return to Amgen, he was CMO of Moderna Therapeutics, with global responsibility for all medical strategy as well as patient safety and pharmacovigilance, from 2021 to 2023. Before that, he spent 16 years at Johnson & Johnson, where his last role was Chief Global Medical Affairs Officer.

Burton has more than 20 years of biopharmaceutical industry experience, across all phases of drug discovery and development, spanning small and large molecules as well as mRNA therapeutics. He has also worked across multiple therapeutic areas, including oncology, cardiovascular and metabolic disease, and infectious diseases.

Burton is a physician trained at University of London, in the United Kingdom. He received post graduate training in cardiovascular surgery, and he holds a PhD in molecular and cellular biology from Imperial College, London. He is a Member of the Royal College of Surgeons, a Fellow of the American College of Cardiology, an elected Fellow of the Royal College of Physicians, and has published extensively in clinical and digital medicine.

Eva-Maria, Head of Healthcare and Lifesciences EMEA at NVIDIA, brings over 15 years experience in healthcare, strategy, and innovation, having worked with the English NHS, the World Economic Forum, Bain & Company, and VMware. She is dedicated to developing AI-powered tools for healthcare, aiming to improve global health outcomes.

Eva-Maria holds a PhD in Engineering Design from the University of Cambridge and a master’s in Physics from the University of Regensburg.

John is a graduate of RCSI and qualified as a Radiologist in 2005. He did fellowships in MRI (Body, Neuro & MSK) & Cardiovascular Imaging in Northwestern Memorial Hospital, Chicago, 2006-2009 and was appointed Chief of Cardiovascular Imaging, NorthShore University Health System, Chicago in 200John currently practices as a Consultant Radiologist in Blackrock Health (Hermitage & Blackrock Clinic’s) and Mobile Medical Diagnostics. His practice includes Diagnostic & Interventional Radiology with cross-sectional interests in cardiovascular, hepato-biliary, prostate, MSK, and Colonography.

John is the Clinical Director of Radiology in the Hermitage Clinic, Clinical Director of Mobile Medical Diagnostics, and Clinical Advisor to xWave Technologies (xRefer)He has a passionate accumulated knowledge & experience in existing & emerging technologies in radiology & wider healthcare, including cloud, AI and Augmented Reality to help innovate & influence technology policy, by integrating clinical, digital, healthcare providers & industry realms.

John is a member of the Irish Digital Health Leadership Strategy Group (DHLSG) led by Prof. Martin Curley, comprised of leading digital health entrepreneurs, corporate leaders, clinicians, patients, academics & others. The charter of the group is to agree, align, and accelerate Ireland’s Digital Health Strategy & Action plan – Stay Left, Shift Left, 10x, enabling Ireland to leapfrog in digital health & overall health maturity. Core of the strategy is that digital technology provides an opportunity to provide 10x innovations or improvements, doing healthcare 10x better, faster, cheaper & increased capacity. The ultimate aim is to make Ireland a European leader in Healthcare by 2025 and a Global leader by 2030.

Gerry was a founding member of Dynamic Resources USA then EMEA followed by APAC established in 1994 in NYC . The first global design PM retail company.

After graduating from University in Dublin Gerry moved to NYC where his Buisness flourished working for the new emerging world of retail . For over 30 years, he has designed and delivered spaces for fashion, automotive, and major luxury goods brands Globally. 10,000 projects Globally.

In 2007, Gerry brought Dynamic back to Europe, setting up a headquarters in London and subsequently opening oWices in Dublin and Japan. He pursued his passion for innovation by creating a unique retail academy that serves Europe and North America and is recognised as a leading centre of excellence for training Dynamic Global Partners.

He divides his time between the United States and the EMEA region, focusing on developing new client relationships and enhancing existing business operations.

On rare occasions when he is not in the air, you may find him on the water, as boating is one of his major passions. Equally important to Gerry is his commitment to giving back, as he contributes to several charities worldwide.

Cathal Friel is a seasoned serial entrepreneur with a long and successful history and to date has listed five companies on the London Stock Exchange. Cathal serves as Chair and co-founder of hVIVO plc (formerly named Open Orphan plc), where he brings extensive experience in successfully growing public companies, particularly in navigating through M&A transactions. Cathal is also co-founder and Chairman of Poolbeg Pharma plc, a publicly listed biopharmaceutical company which was demerged from hVIVO plc in 2021. Cathal also co-founded and sits on the Board of European Green Transition plc, which listed on London Stock Exchange in April 2024. Cathal co-founded Amryt Pharma plc which listed on the London Stock Exchange in 2016 and dual listed on Nasdaq in 2020 and was later sold to Chiesi Farmaceutici for $1.48bn in 2023. Prior to that, he was co-founder and Chairman of Fastnet Oil & Gas plc, which listed on the London Stock Exchange in 2011. In 2001, Cathal was part of the team that successfully established Merrion Stockbrokers in Dublin. Following Merrion’s trade sale in 2006, he founded Raglan Capital which is renowned for building in-house companies that are listed on the public stock markets. Cathal was a finalist in the international category of the EY Entrepreneur of the Year 2020.